Skip to main content

Aaron Lucas, PhD, MPH

Authored Items
Budget Impact of Adding Vedolizumab to a Health Plan Formulary as Another First-Line Biologic Option for Ulcerative Colitis and Crohn’s Disease
Michele Wilson, MSPH, Aaron Lucas, PhD, MPH, Ann Cameron, MA, PhD, Michelle Luo, PhD
July 2018 Vol 11, No 5 in Original Research, Practice Management
Last modified: April 11, 2019